Atlas Trials

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Clinical trial NCT07180160 · RECRUITING

Trial details

NCT number
NCT07180160
Sponsor
Wenjin Yin
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Breast Cancer
Start date
2025-09-25
Primary completion
2027-09-01
Enrollment
123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.